CY-QUANT VASP/P2Y12

Back to list

default
Reference
7502
Status
CE
Sample
160 µL citrated  whole blood
Quantity
1 à 23 tests/run
Detection
ELISA
Application
ELISA Kits
Form

Coated microtiter plate, PGE1, PGE1 + ADP, Lysis buffer,Washing solution, Dilution buffer, Anti-VASP-P peroxidase, TMB, Stop solution, tool to extract wells from their strips

CY-QUANT VASP/P2Y12 kit is dedicated to the measurement of specific platelet ADP receptor (P2Y12) antagonists. VASP (Vasodilator Stimulated Phosphoprotein) is an intracellular platelet protein which is unphosphorylated at basal state. Prostaglandin E1 (PGE1) induces phosphorylation of VASP, whereas the binding of adenosine diphosphate (ADP) to P2Y12 receptors leads to dephosphorylation of VASP. Under test conditions, in the concomitant addition of ADP and PGE1, the effect of ADP dominates and leads to VASP dephosphorylation, unless the P2Y12 receptor is efficiently blocked by antiplatelet drugs targeting this receptor (such as thienopyridines). Thus, the level of VASP phosphorylation in this condition reflects the level of P2Y12 receptor inhibition.

Date Document Name Download
01/12/2017 Package insert CY-QUANT VASP P2Y12 DE (144.01 KB)
EN (131.77 KB)
ES (134.38 KB)
FR (135.60 KB)
IT (132.75 KB)
PT (135.36 KB)
01/09/2013 Flyer CY-QUANT VASP P2Y12 EN (726.86 KB)
Author Title Year of edition Review
Barragan P. et al
Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity
2010
Thromb. Haemost
Jakubowski J.A. et al
Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated
2012
Thromb. Haemost
Abtan J et al
Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein
2013
Thromb Haemost
Hobl E.L et al
Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation to assess P2Y12-inhibition after ticagrelor intake
2013
Cytometry
Gaussem P et al.
Inefficacy of Platelet Transfusion to Reverse Ticagrelor
2015
N Engl J Med
Söderlund et al
In vitro anti-platelet potency of ticagrelor in blood samples from infants and children
2015
Thromb Research
Bonello L et al
Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome
2015
Thromb Haemost
Umemura K & Iwaki T.
The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
2016
Clin Pharmacol Drug Dev
Singh D. & Silakari O.
Facile alkylation of 4-nitrobenzotriazole and its platelet aggregation inhibitory activity
2017
Bioorg. Med. Chem.
Ding P. et al.
Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population
2017
Clin Appl Thromb Hemost.
Deharo P. et al
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study
2017
JACC Cardiovasc Interv.
Takehiko Nagao et al
A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial – PRASTRO-I trial
2018
Expert Opinion on Pharmacotherapy
Deepak L. Bhatt et al
Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
2019
The New England Journal of Medicine
Holm M. et al
The MOVEMENT Trial
2019
Journal of the American Heart Association
Ito Y. et al
Vasodilator-stimulated phosphoprotein (VASP) is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and antiplatelet effect of prasugrel in rats.
2018
International Journal of Scientific Reports
Bonello L. et al
Parameters of complete blood count do not predict on-treatment platelet reactivity in acute coronary syndrome patients.
2017
Thrombosis Research
Zeymer U. et al
Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention
2015
JACC: Cardiovascular Interventions
Martin A. et al.
Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach
2020
Eur J Pharmacol.